{
  "id": 9336190,
  "title": "FDA Approves Lilly’s New Oral Combo Pill for Common Breast Cancer Mutation",
  "url": "https://urgent.news/2026/09/23/fda-approves-lillys-new-oral-combo-pill-for-common-breast-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-23T10:56:42.000Z",
  "source": {
    "name": "Healthline News",
    "slug": "healthline-news",
    "url": "https://www.healthline.com/health-news/fda-approves-eli-lilly-oral-combo-drug-common-breast-cancer-mutation"
  },
  "original_language": "en",
  "account": null,
  "summary": "The Eli Lilly corporate headquarters in Indianapolis, IN, on August 15, 2024. AJ Mast/Bloomberg via Getty Images The FDA approved a new oral combo drug for a common breast cancer mutation on September 18. The treatment includes Inluriyo (imlunestrant) taken with Verzenio (abemaciclib) for adults with ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutation that has…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}